
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT
- About


Galecto Inc (GLTO)



- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)


(see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
06/27/2025: GLTO (1-star) is currently NOT-A-BUY. Pass it for now.
1 Year Target Price $6
1 Year Target Price $6
1 | Strong Buy |
0 | Buy |
1 | Hold |
0 | Sell |
0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -79.4% | Avg. Invested days 44 | Today’s Advisory PASS |
Upturn Star Rating ![]() ![]() | Upturn Advisory Performance ![]() | Stock Returns Performance ![]() |
![]() ![]() | ![]() ![]() |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 4.52M USD | Price to earnings Ratio - | 1Y Target Price 6 |
Price to earnings Ratio - | 1Y Target Price 6 | ||
Volume (30-day avg) 2 | Beta 1.32 | 52 Weeks Range 2.01 - 16.07 | Updated Date 06/30/2025 |
52 Weeks Range 2.01 - 16.07 | Updated Date 06/30/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -15.4 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -35.94% | Return on Equity (TTM) -88.35% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value -5983533 | Price to Sales(TTM) - |
Enterprise Value -5983533 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA 0.46 | Shares Outstanding 1322360 | Shares Floating 1215565 |
Shares Outstanding 1322360 | Shares Floating 1215565 | ||
Percent Insiders 3.59 | Percent Institutions 13.05 |
Analyst Ratings
Rating 2 | Target Price 6 | Buy - | Strong Buy 1 |
Buy - | Strong Buy 1 | ||
Hold 1 | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Galecto Inc

Company Overview
History and Background
Galecto, Inc. is a biotechnology company focused on developing novel treatments for fibrosis and cancer. Founded in 2011, it has progressed through preclinical and clinical stages, primarily concentrating on galectin inhibitors.
Core Business Areas
- Fibrosis Drug Development: Develops galectin-3 inhibitors to treat fibrotic diseases, including liver, lung, and kidney fibrosis.
- Cancer Immunotherapy: Explores the use of galectin inhibitors in combination with cancer immunotherapy to enhance treatment efficacy.
Leadership and Structure
The leadership team includes Hans Schambye (CEO) and other executives with backgrounds in pharmaceutical development and commercialization. The organizational structure is typical of a biotechnology company, with research, clinical development, and commercial operations departments.
Top Products and Market Share
Key Offerings
- GB0139: An inhaled formulation of a galectin-3 inhibitor being developed for idiopathic pulmonary fibrosis (IPF). Market share is currently 0% as the product is in clinical trials. Competitors in the IPF market include Boehringer Ingelheim (Ofev) and Roche (Esbriet).
- GB1211: An oral galectin-3 inhibitor being developed for liver fibrosis and NASH. Market share is currently 0% as the product is in clinical trials. Competitors in the NASH market include Madrigal Pharmaceuticals (Resmetirom) and Viking Therapeutics (VK2809).
Market Dynamics
Industry Overview
The biotechnology industry is characterized by high R&D costs, long development timelines, and regulatory hurdles. The fibrosis and cancer markets are large and growing, driven by aging populations and increasing prevalence of chronic diseases.
Positioning
Galecto is positioned as a specialist in galectin biology, focusing on developing galectin inhibitors for fibrotic diseases and cancer. Their competitive advantage lies in their proprietary galectin inhibitor platform.
Total Addressable Market (TAM)
The TAM for fibrosis and NASH therapeutics is estimated to be over $20 billion annually. Galecto is positioned to capture a share of this market if its clinical trials are successful and products are approved.
Upturn SWOT Analysis
Strengths
- Proprietary galectin inhibitor platform
- Experienced leadership team
- Focus on unmet medical needs
- Clinical-stage product pipeline
Weaknesses
- Limited financial resources
- Reliance on clinical trial success
- Competition from established pharmaceutical companies
- High R&D costs
Opportunities
- Positive clinical trial results
- Partnerships with larger pharmaceutical companies
- Expansion into new indications
- Increased awareness of galectin biology
Threats
- Clinical trial failures
- Regulatory setbacks
- Competition from new therapies
- Patent expirations
Competitors and Market Share
Key Competitors
- BI
- RHHBY
- MRVL
- VKTX
Competitive Landscape
Galecto faces competition from established pharmaceutical companies with greater resources and broader product portfolios. Its competitive advantage lies in its focus on galectin biology and its proprietary galectin inhibitor platform. However, it is in direct competition with companies developing drugs for the same or similar indications.
Growth Trajectory and Initiatives
Historical Growth: Historical growth is primarily reflected in the advancement of its clinical pipeline and expansion of its research programs.
Future Projections: Future growth depends on the successful completion of clinical trials and regulatory approvals for its lead product candidates. Analyst estimates will vary based on their assessments of the company's pipeline and market potential.
Recent Initiatives: Recent initiatives include advancing GB0139 and GB1211 through clinical trials, exploring new indications for its galectin inhibitors, and seeking potential partnerships.
Summary
Galecto is a clinical-stage biopharmaceutical company focused on galectin inhibitors, primarily for fibrosis and cancer. While it holds promise with its innovative approach, its success is heavily dependent on positive clinical trial outcomes and regulatory approvals. The company faces intense competition and relies on securing funding to sustain its operations. Success in clinical trials and commercialization are key milestones to watch for.
Peer Comparison
Sources and Disclaimers
Data Sources:
- SEC Filings
- Company Website
- Analyst Reports
- Industry Reports
Disclaimers:
This analysis is for informational purposes only and should not be considered investment advice. The information provided is based on publicly available data and analyst estimates, which are subject to change. Investment decisions should be made based on individual financial circumstances and consultation with a qualified financial advisor.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Galecto Inc
Exchange NASDAQ | Headquaters - | ||
IPO Launch date 2020-10-29 | Co-Founder, President, CEO & Director Dr. Hans T. Schambye M.D., Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 5 | Website https://galecto.com |
Full time employees 5 | Website https://galecto.com |
Galecto, Inc., a clinical-stage biotechnology company, develops molecule therapeutics for the treatment of fibrosis, cancer, inflammation, and other related diseases. The company develops GB3226, a preclinical small molecule dual inhibitor of ENL-YEATS and FLT3 and GB1211, an oral small molecule inhibitor of galectin-3 to treat multiple types of oncology and liver disease indications. Galecto, Inc. was founded in 2011 and is headquartered in Copenhagen, Denmark.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.